# DESCRIPTION

## REFERENCE TO A “SEQUENCE LISTING,” A TABLE, OR A COMPUTER PROGRAM LISTING APPENDIX SUBMITTED AS AN ASCII TEXT FILE

- reference sequence listing

## BACKGROUND OF THE INVENTION

- introduce Zika virus
- discuss flaviviruses
- summarize existing vaccines
- identify need for improved compositions

## SUMMARY OF THE INVENTION

- introduce composition
- describe nucleoside-modified RNA
- specify ZIKV antigen
- provide embodiment of nucleoside-modified RNA
- describe embodiment of ZIKV antigen
- specify SEQ ID NO: 2
- specify SEQ ID NO: 1
- describe vaccine
- describe adjuvant
- describe lipid nanoparticle (LNP)
- describe LNP structure Formula (I)
- describe LNP structure Formula (II)
- describe LNP structure Formula (III)
- describe pegylated lipid structure (IV)
- describe pegylated lipid structure (IVa)
- describe method of inducing immune response

## DETAILED DESCRIPTION

- introduce compositions and methods for inducing immune response against ZIKV
- describe various embodiments of the invention

### Definitions

- define 'a' and 'an'
- define 'about'
- define 'antibody'
- define 'antibody fragment'
- define 'antibody heavy chain'
- define 'antibody light chain'
- define'synthetic antibody'
- define 'antigen'
- define 'adjuvant'
- define 'disease'
- define 'disorder'
- define 'effective amount'
- define 'encoding'
- define 'expression vector'
- define 'homologous'
- define 'immunogen'
- define 'immune response'
- define 'isolated'
- define 'nucleotide sequence encoding an amino acid sequence'
- define'modulating'
- define 'nucleoside-modified nucleic acid'
- define 'operably linked'
- define 'patient'
- define 'peptide'
- define 'polynucleotide'
- define 'promoter'
- define'specifically binds'
- define 'therapeutic'
- define 'therapeutically effective amount'
- define 'treat'
- define 'transfected'
- define 'transformed'
- define 'transduced'
- define 'under transcriptional control'
- define'vector'
- describe ranges
- define 'nucleoside-modified RNA'
- define 'lipid nanoparticle (LNP)'
- define 'adjuvant'
- define 'nucleoside-modified RNA encoding an adjuvant'

### DESCRIPTION

- introduce compositions and methods for inducing immune response against ZIKV
- describe composition comprising nucleic acid molecule encoding ZIKV antigen
- describe induced immune response
- describe composition comprising IVT RNA
- describe nucleoside-modified RNA encoding ZIKV antigen
- describe composition comprising LNP
- describe method for inducing immune response against ZIKV

### Vaccine

- define immunogenic composition
- describe vaccine composition
- explain immunogenic response
- detail antigen presentation
- describe CTL induction
- outline CTL detection methods
- discuss antibody production
- explain CD4+ T cell response
- describe therapeutic administration
- outline prophylactic administration
- discuss prevention levels
- describe disease prevention
- explain disease treatment
- summarize vaccine composition

### Antigen

- define ZIKV antigen
- describe nucleic acid sequence
- detail polypeptide or peptide antigen
- outline fragment of polypeptide or peptide
- list ZIKV proteins
- describe signal peptide
- detail SP-prM-E composition
- outline nucleoside-modified RNA
- describe ZIKV strain
- explain homologous amino acid sequence
- summarize antigen composition

### Adjuvant

- define adjuvant composition
- list exemplary adjuvants
- describe lipid nanoparticle adjuvant

### Nucleic Acids

- define nucleoside-modified nucleic acid molecule
- encode ZIKV antigen
- encode plurality of antigens
- induce adaptive immune response
- encode adjuvant
- define substantially homologous nucleotide sequences
- describe modifications to nucleotide sequences
- define substantially homologous amino acid sequences
- describe modifications to amino acid sequences
- introduce construct with nucleotide sequence
- encode ZIKV antigen in construct
- encode plurality of ZIKV antigens in construct
- encode adjuvant in construct
- describe composition with plurality of constructs
- introduce translational control element
- form expression cassette
- obtain nucleic acid sequences using recombinant methods
- clone nucleic acid into vector
- describe types of vectors
- introduce chemical means for introducing polynucleotide
- describe liposome delivery vehicle
- associate nucleic acid with lipid
- describe lipid formulations
- confirm presence of mRNA sequence
- describe molecular biological assays
- describe biochemical assays
- introduce in vitro transcribed RNA
- encode ZIKV antigen in IVT RNA
- encode plurality of ZIKV antigens in IVT RNA
- encode adjuvant in IVT RNA
- describe template for in vitro transcription
- modify UTR lengths for optimal translation efficiency
- introduce conventional method of integration of polyA/T stretches
- limitations of molecular cloning
- use of recombination incompetent bacterial cells
- extend poly(A) tails of RNAs
- increase translation efficiency of RNA
- attach chemical groups to 3′ end
- provide stability to mRNA molecules
- generate 5′ cap1 structure
- introduce RNA into target cells
- describe nucleoside-modified RNA
- advantages of nucleoside-modified mRNA
- benefits of mRNA over protein, plasmid DNA, or viral vectors
- describe nucleoside-modified RNA comprising pseudouridine
- suppress innate immunogenicity
- improve stability of RNA
- purify nucleoside-modified nucleic acid molecule
- encompass RNA, oligoribonucleotide, and polyribonucleotide molecules
- define nucleoside-modified RNA
- describe synthesis methods
- list modified nucleosides
- describe combinations of modifications
- specify fraction of modified residues
- describe fraction ranges
- specify fraction of modified residues for each nucleoside
- describe translation efficiency
- specify translation enhancement factors
- describe adaptive immune response
- specify adaptive immune response enhancement factors
- define significantly more robust adaptive immune response
- describe reduced innate immunogenicity
- specify innate immunogenicity reduction factors
- define significantly less innate immunogenicity
- describe reduced innate immunogenicity effects
- list additional modified nucleosides
- describe additional combinations of modifications
- specify additional fraction ranges
- describe additional translation efficiency enhancements
- specify additional adaptive immune response enhancements
- describe additional reduced innate immunogenicity effects
- list more modified nucleosides
- describe more combinations of modifications
- specify more fraction ranges
- describe more translation efficiency enhancements
- specify more adaptive immune response enhancements
- describe more reduced innate immunogenicity effects
- list even more modified nucleosides
- describe even more combinations of modifications
- specify even more fraction ranges
- describe even more translation efficiency enhancements
- specify even more adaptive immune response enhancements
- describe even more reduced innate immunogenicity effects
- list additional modified nucleosides
- describe additional combinations of modifications
- specify additional fraction ranges
- summarize nucleoside-modified RNA properties

### Lipid Nanoparticle

- introduce lipid nanoparticle (LNP)
- define LNP composition
- describe LNP formation
- motivate LNP use
- describe liposome structure
- describe liposome function
- describe LNP advantages
- introduce cationic lipid
- define cationic lipid
- describe cationic lipid function
- list cationic lipid examples
- introduce amino lipid
- define amino lipid
- describe amino lipid function
- list amino lipid examples
- describe dilinoleyl amino lipid
- introduce DLin-K-DMA
- describe DLin-K-DMA structure
- describe DLin-K-DMA function
- introduce Formula (I)
- describe Formula (I) structure
- describe Formula (I) function
- list Formula (I) embodiments
- describe L1 and L2 options
- describe R8 and R9 options
- describe carbon-carbon double bond options
- conclude LNP description
- define lipid compound structure
- specify embodiments of a, b, c, and d
- specify embodiments of a
- specify embodiments of b
- specify embodiments of c
- specify embodiments of d
- specify relationships between a, b, c, and d
- specify embodiments of e
- specify embodiments of R1a, R2a, R3a, and R4a
- specify embodiments of R1b, R2b, R3b, and R4b
- specify embodiments of R5 and R6
- specify embodiments of R7
- specify embodiments of R8 and R9
- introduce lipid nanoparticle composition
- define lipid of Formula (II)
- specify embodiments of L1 and L2
- specify embodiments of G1 and G2
- specify embodiments of R1a, R1b, R2a, R2b, R3a, R3b, R4a
- specify embodiments of R4b
- specify embodiments of R5, R6, R7, R8, and R9
- specify embodiments of lipid compound structures (IIA), (IIB), (IIC), and (IID)
- define lipid nanoparticle
- describe structure IIC
- describe structure IID
- specify e, f, g, and h
- specify a
- specify b
- specify c
- specify d
- specify e and f
- specify g and h
- describe sum of a and b, and sum of c and d
- describe R1a, R2a, R3a, and R4a
- describe R1b, R2b, R3b, and R4b
- describe R5 and R6
- describe R7
- describe R8 and R9
- describe G3
- describe lipid compound structures
- describe LNP composition
- define lipid of Formula III
- describe lipid structures of Formula III
- define lipid nanoparticle
- describe structure of lipid nanoparticle
- specify components of lipid nanoparticle
- describe cationic lipid of Formula (III)
- specify R6 in Formula (III)
- specify G3 in Formula (III)
- specify R1 or R2 in Formula (III)
- describe structure of R1 and R2
- specify R7a and R7b
- describe R3 in Formula (III)
- specify structures of R3
- describe neutral lipids
- specify examples of neutral lipids
- describe anionic lipids
- specify examples of anionic lipids
- describe pegylated lipids
- specify examples of pegylated lipids
- describe structure of pegylated lipid (IV)
- specify R10 and R11 in Formula (IV)
- specify z in Formula (IV)
- describe additional lipids in lipid nanoparticle
- specify amount of additional lipid in lipid nanoparticle
- describe targeting moieties in lipid nanoparticle
- describe internalization domains in lipid nanoparticle
- describe reaction schemes for making lipids of Formula (I), (II), or (III)
- describe General Reaction Scheme 1 (Method A)
- describe General Reaction Scheme 2 (Method B)
- describe General Reaction Scheme 3 (Method C)
- describe General Reaction Scheme 4 (Method D)
- describe General Reaction Scheme 5 (Method E)
- describe General Reaction Scheme 6 (Method F)
- note alternative strategies for preparing lipids of Formula (III)
- note use of protecting groups in synthesis
- specify examples of protecting groups
- describe addition and removal of protecting groups
- reference Green, T. W. and P. G. M. Wutz, Protective Groups in Organic Synthesis

### Pharmaceutical Compositions

- prepare pharmaceutical compositions
- associate active ingredient with carrier or accessory ingredients
- shape or package product into single- or multi-dose unit
- modify compositions for administration to animals
- contemplate administration to various subjects
- formulate for ophthalmic, oral, rectal, vaginal, parenteral, topical, pulmonary, intranasal, buccal, intravenous
- formulate projected nanoparticles, liposomal preparations, resealed erythrocytes
- prepare in bulk, single unit dose, or plurality of single unit doses
- define unit dose
- vary relative amounts of active ingredient, carrier, and additional ingredients
- include additional pharmaceutically active agents
- make controlled- or sustained-release formulations
- define parenteral administration
- formulate for parenteral administration
- prepare injectable formulations
- formulate sterile injectable aqueous or oily suspension or solution
- include dispersing, wetting, or suspending agents
- formulate for pulmonary administration
- prepare dry powder compositions
- include low boiling propellants
- define additional ingredients
- include excipients, surface active agents, dispersing agents, etc.
- reference Remington's Pharmaceutical Sciences

### Treatment Methods

- induce adaptive immune response against ZIKV
- provide immunity to ZIKV, infection, or disease
- treat or prevent infection, disease, or disorder associated with ZIKV
- administer to subject having infection, disease, or disorder
- administer to subject at risk for developing infection, disease, or disorder
- administer to subject who lives in, traveled to, or is expected to travel to ZIKV-prevalent region
- administer to subject who is in contact with or expected to be in contact with another person
- administer to subject who has knowingly been exposed to ZIKV
- administer to pregnant or potentially pregnant subject
- induce immune response against ZIKV in embryo, fetus, or unborn child
- administer composition with nucleoside-modified nucleic acid molecules and adjuvant
- administer composition with first and second nucleoside-modified nucleic acid molecules
- administer multiple nucleoside-modified nucleic acid molecules
- allow for sustained expression of ZIKV antigen or adjuvant
- provide sustained protection against ZIKV
- administer composition systemically, intradermally, intravenously, intramuscularly, subcutaneously, or intranasally
- administer composition alone or with another agent

## EXPERIMENTAL EXAMPLES

- provide illustrative examples

### Example 1: Zika Virus Protection by a Single Low-Dose Nucleoside-Modified mRNA Vaccination

- demonstrate Zika virus protection
- describe experimental methods
- list antibody reagents
- list protein reagents
- describe mRNA production
- describe cell culture
- describe mRNA transfection
- analyze envelope protein expression
- characterize E protein in supernatant
- formulate lipid nanoparticles
- administer LNPs to mice and monkeys
- collect blood from mice and monkeys
- stimulate and stain splenocytes
- perform flow cytometry
- perform ELISA for ZIKV E-specific IgG
- describe Western blot analysis
- describe mRNA transfection reagents
- describe cell culture medium
- describe mRNA purification
- describe LNP composition
- describe ELISA protocol
- measure ZIKV E-protein-specific IgG
- perform PRNT
- calculate neutralization titers
- describe FRNT protocol
- calculate FRNT50
- produce RVPs
- determine RVP titers
- perform RVP neutralization assay
- calculate EC50 titers
- prepare challenge ZIKV virus for mice
- prepare challenge ZIKV virus for monkeys
- perform Zika virus challenge in mice
- perform Zika virus challenge in monkeys
- determine viral loads in plasma
- introduce Zika virus protection
- describe viral load quantification
- outline statistical analysis
- motivate mRNA as vaccine modality
- describe advantages of mRNA vaccination
- introduce nucleoside-modified mRNA vaccine
- describe in vitro characterization
- evaluate immune response in mice
- analyze T cell responses
- describe antibody responses
- measure neutralizing antibodies
- evaluate protection in mice
- introduce immunogenicity in BALB/c mice
- analyze antibody responses in BALB/c mice
- evaluate protection in BALB/c mice
- introduce challenge study in BALB/c mice
- evaluate protection in rhesus macaques
- analyze antibody responses in rhesus macaques
- evaluate protection in rhesus macaques
- compare to other vaccine candidates
- discuss durability of protection
- discuss relevance to ZIKV pathogenesis
- discuss advantages of mRNA-LNP vaccine
- conclude and provide disclaimer

